Amgen’s Denosumab, GTx’s Toremifene Keep Pace At ASCO On Prevention Of Bone Fractures In Prostate Cancer Patients

Both firms have October user fee dates for prevention of bone fracture risk in prostate cancer patients on androgen deprivation therapy, and both report favorable incremental data.